Which of the following statements are true?
Patients with prediabetes…
A. have an increased incidence of polyneuropathy.
B. have a decreased incidence of polyneuropathy.
C. have the same incidence of polyneuropathy as the general population.
According to the American Diabetes Association, before people develop type 2 diabetes, they almost always have “prediabetes” — blood glucose levels that are higher than normal but not yet high enough to be diagnosed as diabetes. Also known as impaired glucose tolerance, prediabetes is an epidemic by any definition. In 2015, acording to the CDC, 34% of all US adults, 84 million people, were prediabetic. It is estimated that currently over 100 million Americans are prediabetic.
It has long been postulated and recent studies from Canada and the UK have found that individuals with prediabetics are at greater risk of having polyneuropathy than non-diabetics. The incidence of polyneuropathy in prediabetics appears to be equal to that of newly diagnosed diabetics, in the range of 10%.
The correct answer is:
A. Patients with prediabetes have an increased incidence of polyneuropathy.
So, when a patient presents with polyneuropathy, look for prediabetes.
This Neuropathy Nugget is authored Dr. Richard Mann, CEO and Founder of Realm Labs, makers of NeuRemedy®. Feel free to contact Dr. Mann at (561)-549-9099 or email@example.com if you would like to discuss with him ways in which you can more effectively treat polyneuopathy in your office.
NeuRemedy® improves the function of the nerves in the feet and legs. NeuRemedy® is licensed by Health Canada to support the healthy function of nerves in individuals with polyneuropathy.* To begin dispensing NeuRemedy in your office call (561)-549-9099 today.
Be sure to check out Neuropathy Nugget #3: Does the use of metformin impact thiamine (vitamin B1) utilization?
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.